(MedPage Today) — The FDA halted studies of two investigational gene therapies for rare pediatric diseases after a child treated in a clinical trial developed a brain tumor, RegenxBio said Wednesday.
The holds affect RGX-111 and RGX-121, therapies…
Source link : https://www.medpagetoday.com/neurology/generalneurology/119638
Author :
Publish date : 2026-01-29 14:12:00
Copyright for syndicated content belongs to the linked Source.
